Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9710472 | 0.93 | HDAC8 (0.44) | HDAC8SLC7A5 | |
| SCHEMBL1986119 | 0.83 | OPRM1 (0.50) | OPRD1OPRM1 | |
| SCHEMBL10914916 | 0.82 | GAA (0.40) | — | |
| SCHEMBL10490158 | 0.81 | MAPT (0.45) | — | |
| SCHEMBL156774 | 0.78 | MAPT (0.55) | — | |
| SCHEMBL30486022 | 0.78 | MAPT (0.55) | — | |
| SCHEMBL9410025 | 0.77 | MAPT (0.42) | — | |
| SCHEMBL9710474 | 0.77 | HDAC8 (0.42) | HDAC8SLC7A5 | |
| SCHEMBL28787105 | 0.75 | MAPT (0.53) | — | |
| SCHEMBL27398624 | 0.75 | MAPT (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030341-B2 | Dual delta and mu opioid receptor antagonist; 3,6-Bis(Boc-Dmt-Tic-NH-methyl)-2(1H)-pyrazinone | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080269143-A1 | Dmt-Derivative Compounds and Related Compositions and Methods of Use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007027628-A1 | DMT-DERIVATIVE COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269143-A1 | Dmt-Derivative Compounds and Related Compositions and Methods of Use | OPRM1, OPRD1, OPRK1 | HDAC8 2980/4885SLC7A5 1747/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.